Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent - Full Text View

Purpose

The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal. However, the transformation of HIV into a chronic disease needing lifelong antiretroviral treatment (ART) raises new challenges, among others related to a disturbance of glucose metabolism, lipid abnormalities, in addition to the potential effects on children's growth and puberty. Little is known on nutritional and metabolic changes in HIV-infected children on ART in Africa, while implementation of the latest WHO recommendations should eventually lead to an increase in the number of children on ART in this region. Moreover, bio-clinical evolution of untreated children is poorly documented in the African context. It therefore urgently needed to institute a cohort study to evaluate, in the long term, the impact of HIV infection and/or ART on nutritional and metabolic disorders and to characterize the risk factors of their occurrence in children and adolescents infected as they move through adolescent into adulthood.

Condition
HIV-1


Study Type:	Observational [Patient Registry]
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration:	3 Years
Official Title:	Assessment of Risk Factors of Nutritional and Metabolic Disorders in Children and Adolescent Receiving or Not Antiretroviral Treatment : Growing up With HIV in Senegal

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Metabolic Disorders

U.S. FDA Resources

Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

Primary Outcome Measures:

Prevalence of delayed growth [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores
Prevalence of delayed puberty [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Delayed puberty is assessed by age of entry into puberty and the age of transition to different Tanner staging
Prevalence of lipodystrophy [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Lipodystrophy (lipoatrophy, lipohypertrophy, combined forms) is defined by direct observation and by joint analysis of anthropometric measures associated with fat tissue index and lean tissue index measured by electrical bio-impedancemetry
Prevalence of blood lipids ans glucose abnormalities [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides
Incidence of delayed growth [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]
Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores
Incidence of delayed puberty [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]
Assessed by age of entry into puberty and the age of transition to a different Tanner stage
Incidence of lipodystrophy [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]
defined by direct observation and by joint analysis of anthropometric measures associated with changes in fat tissue index and lean tissue index measured by electrical bio-impedancemetry
Incidence of blood lipid and glucose abnormalities [ Time Frame: Annually for 3 years from the anniversary date of the study ] [ Designated as safety issue: No ]
Repeated measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides

Biospecimen Retention: Samples With DNA

Plasma, blood cells and urine samples to be retained


Enrollment:	330
Study Start Date:	April 2013
Study Completion Date:	April 2016
Primary Completion Date:	April 2016 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	2 Years to 15 Years (Child)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV-1 infected individuals age between 2 ans 16 years

Criteria

Inclusion Criteria:

HIV-1 infection
Age equal or above 2 years and bellow 16 years
Follow-up in the participating site
Informed consent signed by at least on of the parents or legal guardian who is aware of the child's HIV status

Exclusion Criteria:

HIV-2 or HIV-1+2 infection
children represented by a legal guardian who is not informed about the child's HIV status
Unable to comply with study requirements or procedures according to the investigator's opinion

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01771562

Locations


Senegal
Hôpital d'enfant Albert Royer
Dakar, Senegal
Hôpital Roi Baudoin
Guédiawaye, Senegal

Sponsors and Collaborators

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Investigators


Principal Investigator:	Philippe Msellati, MD	IRD : French Research Institute for Development
Principal Investigator:	Haby Sy Signate, MD	Hôpital d'Enfant Albert Royer, Dakar, Senegal
Principal Investigator:	Ngagne Mbaye, MD	Hôpital Roi Baudoin, Guédiawaye, Senegal

More Information

Additional Information:

Sponsor website This link exits the ClinicalTrials.gov site


Responsible Party:	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:	NCT01771562 History of Changes
Other Study ID Numbers:	ANRS 12279 MAGGSEN
Study First Received:	January 16, 2013
Last Updated:	May 19, 2016
Health Authority:	Senegal: Ministry of Health and Social Action

Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):


HIV-1 Child Adolescent Growth	Lipodystrophy ARV treatment Senegal

Additional relevant MeSH terms:


Metabolic Diseases

ClinicalTrials.gov processed this record on September 23, 2016